Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Resistance news

Show

From To
HIV rapidly develops resistance to gene-editing cure technology

In a setback for a novel approach to curing HIV, researchers involved in a technique that uses enzymes to remove viral genes from the DNA of infected

Published
17 May 2016
By
Gus Cairns
Outbreak of high level azithromycin resistant gonorrhoea in England

There have been 34 cases of high level azithromycin resistant gonorrhoea amongst residents of England between November 2014 and April 2016. The outbreak spread from the north of England to the West Midlands and south of England, including London. Initial cases were among heterosexuals but more recent evidence suggests high level azithromycin resistant gonorrhoea is now spreading among men who have sex with men.

Published
15 April 2016
From
Public Health England
Resistance to anti-HIV drugs in steep decline in Switzerland

Prevalence of antiretroviral drug resistance has declined significantly among patients in Switzerland, investigators report in the online edition of Clinical Infectious Diseases. As many as 57% of

Published
13 April 2016
By
Michael Carter
Nigerian herbal medicines widely used by HIV positive people can contain antiretrovirals

Herbal medicine use among HIV positive people in Nigeria is widespread, poorly recorded and often precedes ART initiation. Contamination with antiretrovirals is possible and concerning, particularly in untreated people, say the authors of a study of herbal medicine presented at CROI 2016.

Published
24 March 2016
From
HIV i-Base
Combination inhibitor BMS-986197 demonstrates good activity against HIV in early study

A long-acting bio-engineered molecule with a triple mechanism of action demonstrated potent antiviral activity and worked against HIV that developed resistance to any one of the three

Published
18 March 2016
By
Liz Highleyman
Dr. Robert Grant weighs in after the first case of failed PrEP: What does it mean?

At CROI today, researchers and providers heard a detailed case study of a man who was infected with drug-resistant HIV while taking PrEP. No study to date has definitively documented a “breakthrough” HIV infection during PrEP with adherence to Truvada, so the report has garnered a lot of attention and concern from community members. We spoke with Robert Grant, MD, MPH, to give context to the discussion about what this case means for people currently taking PrEP.

Published
26 February 2016
From
BETA blog
Almost-certain case of PrEP failure due to drug resistance reported at CROI 2016

A case report of a man in Toronto who became infected with a multi-drug-resistant strain of HIV despite apparently very consistent adherence to PrEP was presented at

Published
25 February 2016
By
Gus Cairns
What is a drug “tail,” and what does it have to do with long-acting PrEP?

Drug “tails” are a hot topic at CROI 2016 as attendees wait to hear results from a long-acting cabotegravir PrEP injection study with HIV-negative men. A few prominent researchers have already incorporated the issue of drug “tails” into their discussions of one potential downside to having a PrEP drug that stays in a person’s system for an extended length of time.

Published
25 February 2016
From
BETA blog
HIV and drug resistance

A recent study found more resistance to the antiretroviral medicine tenofovir than had previously been reported, with 20% resistance to tenofovir in patients with treatment failure in Europe and over 50% resistance in patients with treatment failure in sub-Saharan Africa... The study underlines the importance of rapidly identifying treatment failure through routine measurement of viral load suppression—this is the basis of the third pillar of UNAIDS’ 90–90–90 treatment target, that 90% of people accessing HIV treatment have suppressed viral loads.

Published
09 February 2016
From
UNAIDS
Tenofovir resistance may develop in more than half of patients failing treatment in sub-Saharan Africa

More than half of people who experienced failure of a tenofovir-based antiretroviral regimen in sub-Saharan Africa had resistance to tenofovir, a meta-analysis of drug resistance studies published

Published
01 February 2016
By
Keith Alcorn

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.